Your browser doesn't support javascript.
loading
Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model.
Gustafsson-Lutz, Anna; Bäck, Tom; Aneheim, Emma; Hultborn, Ragnar; Palm, Stig; Jacobsson, Lars; Morgenstern, Alfred; Bruchertseifer, Frank; Albertsson, Per; Lindegren, Sture.
Afiliação
  • Gustafsson-Lutz A; Department of Radiation Physics, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gula Stråket 2B, 413 45, Gothenburg, Sweden.
  • Bäck T; Department of Radiation Physics, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gula Stråket 2B, 413 45, Gothenburg, Sweden.
  • Aneheim E; Department of Radiation Physics, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gula Stråket 2B, 413 45, Gothenburg, Sweden.
  • Hultborn R; Department of Oncology, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Blå Stråket 2, 413 45, Gothenburg, Sweden.
  • Palm S; Department of Radiation Physics, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gula Stråket 2B, 413 45, Gothenburg, Sweden.
  • Jacobsson L; Department of Radiation Physics, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gula Stråket 2B, 413 45, Gothenburg, Sweden.
  • Morgenstern A; European Commission, Joint Research Centre, Institute for Transuranium Elements, Hermann-von-Helmholtz-Platz 1, 76344, Eggenstein-Leopoldshafen, Germany.
  • Bruchertseifer F; European Commission, Joint Research Centre, Institute for Transuranium Elements, Hermann-von-Helmholtz-Platz 1, 76344, Eggenstein-Leopoldshafen, Germany.
  • Albertsson P; Department of Oncology, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Blå Stråket 2, 413 45, Gothenburg, Sweden.
  • Lindegren S; Department of Radiation Physics, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gula Stråket 2B, 413 45, Gothenburg, Sweden. sture.lindegren@radfys.gu.se.
EJNMMI Res ; 7(1): 38, 2017 Dec.
Article em En | MEDLINE | ID: mdl-28439844
ABSTRACT

BACKGROUND:

The aim of this study was to compare the therapeutic efficacy of two different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model. Sixty female BALB/c (nu/nu) mice were inoculated intraperitoneally with human ovarian cancer cells (OVCAR-3). Two weeks later, 40 mice were injected intraperitoneal (i.p.) with 1 ml of 213Bi-MX35, 3 MBq/mL (n = 20), or 9 MBq/mL (n = 20). An additional 20 mice received unlabeled MX35. Incidence of tumors and ascites was investigated 8 weeks after therapy. Body weight and white blood cell counts were monitored after treatment for possible signs of toxicity.

RESULTS:

The tumor-free fraction of the animals treated with 3 MBq/mL of 213Bi-MX35 was 0.55, whereas that of animals treated with 9 MBq/mL of 213Bi-MX35 was 0.78. The control group treated with unlabeled MX35 had a tumor-free fraction of 0.15. No significant reduction in white blood cell counts or weight loss was observed.

CONCLUSIONS:

Tumor growth after i.p. treatment with 213Bi-MX35 was significantly reduced compared to treatment with unlabeled MX35. Treatment with 9 MBq/mL of 213Bi-MX35 resulted in higher tumor-free fraction compared with 3 MBq/mL of 213Bi-MX35, but this difference was not statistically significant. No signs of toxicity were observed in the treated animals.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article